Q-omics provides the consensus-scored KIAA1107 profile across patient tissues and cancer cell-line models. KIAA1107 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIAA1107 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, KIAA1107 RNA expression shows 21,534 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where KIAA1107 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA1107 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA1107 survival associations across molecular data types. KIAA1107 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA1107 RNA expression–survival associations across cancer types. High KIAA1107 expression shows unfavorable associations in UVM and LIHC, but favorable associations in KIRC, SKCM, READ and PRAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIAA1107 RNA expression.
This table summarizes KIAA1107 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KIAA1107. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA1107 shows lower tumor expression in KICH, UCEC, BRCA and THCA and higher tumor expression in CHOL and LUAD. The KICH box plot shows higher KIAA1107 RNA expression in normal versus tumor tissue (log2 FC = −0.884, t-test p < 0.001).
This table shows molecular features associated with KIAA1107 in patient tissues and cancer cell lines. In patient samples, KIAA1107 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA1107 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
